NASDAQ:GLPG GALAPAGOS NV/S Stock Forecast, Price & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding GALAPAGOS NV/S Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $139.27 -1.84 (-1.30 %) (As of 09/18/2020 12:00 AM ET) Add Compare Share Today's Range$138.05Now: $139.27▼$140.2950-Day Range$122.47MA: $155.62▼$193.8352-Week Range$112.00Now: $139.27▼$274.03Volume95,190 shsAverage Volume155,751 shsMarket Capitalization$9.09 billionP/E Ratio89.28Dividend YieldN/ABeta0.94 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial Media Galapagos NV, a clinical-stage biotechnology company, discovers, develops, and commercializes novel medicines. Its clinical stage programs include filgotinib, which is in Phase III clinical trials for the treatment of rheumatoid arthritis and Crohn's disease, Phase 2/3 trials for ulcerative colitis, and Phase II trials for multiple additional indications; GLPG1690, an autotaxin inhibitor, which is in Phase III clinical trial for the treatment of idiopathic pulmonary fibrosis; GLPG1972 that completed Phase 1b clinical trial for the treatment of osteoarthritis; and MOR106, which is in Phase II trials for atopic dermatitis patients. The company has collaboration agreement with Gilead Sciences, Inc. for the development of filgotinib for inflammatory indications; Servier to develop GLPG1972; AbbVie for the discovery, development, and commercialization of potentiator and corrector molecules for the treatment of cystic fibrosis, as well as with MorphoSys for MOR106; and Evotec AG for the novel target for fibrosis and other indications. Galapagos NV was founded in 1999 and is headquartered in Mechelen, Belgium.Read More Beat the Market (BTM) Rank™ 4.1 Analyst's Opinion Consensus RatingGALAPAGOS NV/S has received a consensus rating of Hold. The company's average rating score is 2.14, and is based on 3 buy ratings, 10 hold ratings, and 1 sell rating.Price Target Upside/DownsideAccording to analysts' consensus price target of $187.75, GALAPAGOS NV/S has a forecasted upside of 34.8% from its current price of $139.27.Amount of Analyst CoverageGALAPAGOS NV/S has been the subject of 8 research reports in the past 90 days, demonstrating strong analyst interest in this stock. Previous Next 2.6 Community Rank Outperform VotesGALAPAGOS NV/S has received 432 “outperform” votes. (Add your “outperform” vote.)Underperform VotesGALAPAGOS NV/S has received 387 “underperform” votes. (Add your “underperform” vote.)Community SentimentGALAPAGOS NV/S has received 52.75% “outperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about GALAPAGOS NV/S and other stocks. Vote “Outperform” if you believe GLPG will outperform the S&P 500 over the long term. Vote “Underperform” if you believe GLPG will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldGALAPAGOS NV/S does not currently pay a dividend.Dividend GrowthGALAPAGOS NV/S does not have a long track record of dividend growth. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, GALAPAGOS NV/S insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 2.91% of the stock of GALAPAGOS NV/S is held by insiders.Percentage Held by InstitutionsOnly 11.58% of the stock of GALAPAGOS NV/S is held by institutions. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for GALAPAGOS NV/S are expected to decrease in the coming year, from ($4.87) to ($5.18) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of GALAPAGOS NV/S is 89.28, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 18.86.Price to Earnings Ratio vs. SectorThe P/E ratio of GALAPAGOS NV/S is 89.28, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 26.31.Price to Book Value per Share RatioGALAPAGOS NV/S has a P/B Ratio of 2.37. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next Analyst Opinion: 4.1Community Rank: 2.6Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -Overall Beat the Market Rank™1.33 out of 5 stars Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:GLPG Previous Symbol CUSIPN/A CIK1421876 Webwww.glpg.com Phone321-534-2900Debt Debt-to-Equity Ratio0.01 Current Ratio9.09 Quick Ratio9.09Price-To-Earnings Trailing P/E Ratio89.28 Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$1.00 billion Price / Sales9.06 Cash Flow$6.36 per share Price / Cash Flow21.90 Book Value$58.75 per share Price / Book2.37Profitability EPS (Most Recent Fiscal Year)$5.46 Net Income$167.83 million Net Margins8.13% Return on Equity8.24% Return on Assets3.82%Miscellaneous Employees1,003 Outstanding Shares65,250,000Market Cap$9.09 billion Next Earnings Date10/22/2020 (Estimated) OptionableOptionable $139.27 -1.84 (-1.30 %) (As of 09/18/2020 12:00 AM ET) 30 days | 90 days | 365 days | Advanced Chart Receive GLPG News and Ratings via Email Sign-up to receive the latest news and ratings for GLPG and its competitors with MarketBeat's FREE daily newsletter. GALAPAGOS NV/S (NASDAQ:GLPG) Frequently Asked Questions How has GALAPAGOS NV/S's stock been impacted by Coronavirus (COVID-19)? GALAPAGOS NV/S's stock was trading at $186.06 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, GLPG shares have decreased by 25.1% and is now trading at $139.27. View which stocks have been most impacted by COVID-19. Do Wall Street analysts recommend investors buy shares of GALAPAGOS NV/S? 14 Wall Street analysts have issued "buy," "hold," and "sell" ratings for GALAPAGOS NV/S in the last year. There are currently 1 sell rating, 10 hold ratings and 3 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View analyst ratings for GALAPAGOS NV/S. When is GALAPAGOS NV/S's next earnings date? GALAPAGOS NV/S is scheduled to release its next quarterly earnings announcement on Thursday, October 22nd 2020. View our earnings forecast for GALAPAGOS NV/S. How were GALAPAGOS NV/S's earnings last quarter? GALAPAGOS NV/S (NASDAQ:GLPG) released its earnings results on Thursday, August, 6th. The biotechnology company reported ($1.95) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($1.07) by $0.88. The biotechnology company had revenue of $129.53 million for the quarter, compared to analysts' expectations of $118.41 million. GALAPAGOS NV/S had a net margin of 8.13% and a return on equity of 8.24%. View GALAPAGOS NV/S's earnings history. What price target have analysts set for GLPG? 14 Wall Street analysts have issued twelve-month price targets for GALAPAGOS NV/S's stock. Their forecasts range from $123.00 to $290.00. On average, they anticipate GALAPAGOS NV/S's stock price to reach $187.75 in the next year. This suggests a possible upside of 34.8% from the stock's current price. View analysts' price targets for GALAPAGOS NV/S. Who are some of GALAPAGOS NV/S's key competitors? Some companies that are related to GALAPAGOS NV/S include Takeda Pharmaceutical (TKPYY), ASTELLAS PHARMA/ADR (ALPMY), Genmab A/S (GMAB), Alexion Pharmaceuticals (ALXN), Beigene (BGNE), Genmab A/S (GNMSF), Shiseido (SSDOY), UCB (UCBJF), Merck KGaA (MKGAF), Horizon Therapeutics (HZNP), Ono Pharmaceutical (OPHLF), Royalty Pharma (RPRX), Alnylam Pharmaceuticals (ALNY), BioMarin Pharmaceutical (BMRN) and Catalent (CTLT). View all competitors. What other stocks do shareholders of GALAPAGOS NV/S own? Based on aggregate information from My MarketBeat watchlists, some companies that other GALAPAGOS NV/S investors own include Gilead Sciences (GILD), CELYAD SA/ADR (CYAD), Intercept Pharmaceuticals (ICPT), NVIDIA (NVDA), argenx (ARGX), AbbVie (ABBV), Pharming Group (PHGUF), Biogen (BIIB), Trade Desk (TTD) and Collegium Pharmaceutical (COLL). Who are GALAPAGOS NV/S's key executives? GALAPAGOS NV/S's management team includes the following people: Mr. Onno van de Stolpe, Co-Founder, MD, CEO & Exec. Director (Age 60)Mr. Bart Filius MBA, CFO & COO (Age 49)Dr. Piet Wigerinck, Chief Scientific Officer (Age 55)Ms. Elizabeth Goodwin, VP of Investor Relations & Corp. CommunicationsDr. Andre Hoekema, Chief Bus. Officer (Age 62) When did GALAPAGOS NV/S IPO? (GLPG) raised $161 million in an IPO on Thursday, May 14th 2015. The company issued 3,800,000 shares at $42.43 per share. Morgan Stanley, Credit Suisse and Cowen and Company acted as the underwriters for the IPO and Nomura and Bryan, Garnier were co-managers. What is GALAPAGOS NV/S's stock symbol? GALAPAGOS NV/S trades on the NASDAQ under the ticker symbol "GLPG." Who are GALAPAGOS NV/S's major shareholders? GALAPAGOS NV/S's stock is owned by a variety of retail and institutional investors. Top institutional investors include Federated Hermes Inc. (2.18%), FMR LLC (1.57%), Cormorant Asset Management LP (0.15%), Alberta Investment Management Corp (0.12%), Public Employees Retirement Association of Colorado (0.08%) and Envestnet Asset Management Inc. (0.07%). Which major investors are selling GALAPAGOS NV/S stock? GLPG stock was sold by a variety of institutional investors in the last quarter, including FMR LLC, Bank of America Corp DE, Peregrine Capital Management LLC, Goldman Sachs Group Inc., Eqis Capital Management Inc., Pinnacle Associates Ltd., Dorsey Wright & Associates, and Sei Investments Co.. Which major investors are buying GALAPAGOS NV/S stock? GLPG stock was bought by a variety of institutional investors in the last quarter, including Federated Hermes Inc., Alberta Investment Management Corp, Marshall Wace North America L.P., Aigen Investment Management LP, Public Employees Retirement Association of Colorado, ETRADE Capital Management LLC, Bank of New York Mellon Corp, and Marshall Wace LLP. How do I buy shares of GALAPAGOS NV/S? Shares of GLPG can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is GALAPAGOS NV/S's stock price today? One share of GLPG stock can currently be purchased for approximately $139.27. How big of a company is GALAPAGOS NV/S? GALAPAGOS NV/S has a market capitalization of $9.09 billion and generates $1.00 billion in revenue each year. The biotechnology company earns $167.83 million in net income (profit) each year or $5.46 on an earnings per share basis. GALAPAGOS NV/S employs 1,003 workers across the globe. What is GALAPAGOS NV/S's official website? The official website for GALAPAGOS NV/S is www.glpg.com. How can I contact GALAPAGOS NV/S? GALAPAGOS NV/S's mailing address is GEN DE WITTELAAN L11 A3, MECHELEN C9, 2800. The biotechnology company can be reached via phone at 321-534-2900 or via email at [email protected] This page was last updated on 9/20/2020 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Questions? Get Started with MarketBeat — Read Your Daily NewsletterCheck Out My MarketBeatWatch Our Tutorial VideosAdd a Stock to Your WatchlistSet Up an Instant AlertView a Company's Profile PageView Our Financial CalendarsView Today's Analyst Ratings
